JY
INMB icon

Jeff Yass’s INmune Bio INMB Stock Holding History

Jeff Yass’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$258K Sell
158,452
-35,939
-18% -$49.7K ﹤0.01% 11379
2026
Q1 		$220K Sell
194,391
-56,519
-23% -$80.5K ﹤0.01% 11508
2025
Q4 		$391K Buy
250,910
+93,956
+60% +$168K ﹤0.01% 9339
2025
Q3 		$325K Buy
156,954
+137,009
+687% +$314K ﹤0.01% 9931
2025
Q2 		$46.1K Sell
19,945
-20,350
-51% -$149K ﹤0.01% 12137
2025
Q1 		$315K Buy
40,295
+16,800
+72% +$133K ﹤0.01% 9969
2024
Q4 		$110K Buy
+23,495
New +$122K ﹤0.01% 11263
2024
Q3 		– Sell
-42,772
Closed -$304K – 12469
2024
Q2 		$377K Sell
42,772
-112,062
-72% -$1.1M ﹤0.01% 8934
2024
Q1 		$1.82M Buy
154,834
+110,998
+253% +$1.34M ﹤0.01% 5555
2023
Q4 		$494K Buy
43,836
+11,995
+38% +$101K ﹤0.01% 8697
2023
Q3 		$218K Sell
31,841
-9,170
-22% -$76K ﹤0.01% 10048
2023
Q2 		$372K Sell
41,011
-29,626
-42% -$238K ﹤0.01% 8996
2023
Q1 		$456K Buy
70,637
+56,343
+394% +$454K ﹤0.01% 8790
2022
Q4 		$90.6K Sell
14,294
-9,479
-40% -$67.3K ﹤0.01% 11043
2022
Q3 		$147K Buy
+23,773
New +$209K ﹤0.01% 11266
2022
Q2 		– Sell
-52,042
Closed -$387K – 13380
2022
Q1 		$438K Sell
52,042
-38,536
-43% -$346K ﹤0.01% 9314
2021
Q4 		$924K Buy
90,578
+8,049
+10% +$119K ﹤0.01% 7515
2021
Q3 		$1.6M Buy
82,529
+6,815
+9% +$132K ﹤0.01% 6312
2021
Q2 		$1.33M Buy
75,714
+42,642
+129% +$575K ﹤0.01% 6961
2021
Q1 		$393K Buy
+33,072
New +$595K ﹤0.01% 10022
2020
Q2 		– Sell
-11,443
Closed -$38K – 10495
2020
Q1 		$38K Buy
+11,443
New +$51.7K ﹤0.01% 9766

Other funds holding INMB

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return

Jeff Yass's INMB Position: Q2 2026 in Review

Jeff Yass reduced its INmune Bio (INMB) stake by 18% in Q2 2026, selling an estimated $49.7K and leaving 158,452 shares worth $258K. The position accounts for ﹤0.01% of the portfolio, ranked #11379.

Jeff Yass first reported a position in INMB in Q1 2020 and has held it in 21 quarters since. The position peaked at $1.82M in Q1 2024. 83 funds tracked by Wall St. Rank hold INMB as of Q2 2026.

  • Jeff Yass held 158,452 shares of INmune Bio worth $258K as of Q2 2026.
  • Jeff Yass sold 35,939 INmune Bio shares in Q2 2026, an estimated $49.7K.
  • INmune Bio made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #11379 holding.
  • Jeff Yass first reported a position in INmune Bio in Q1 2020 and has held it in 21 quarters since.
  • Jeff Yass's INmune Bio position peaked at $1.82M in Q1 2024.
  • 83 funds tracked by Wall St. Rank held INmune Bio as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.